Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
NCT ID: NCT04254640
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
34 participants
INTERVENTIONAL
2021-03-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
C-CAG
cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
Cladribine Injection
Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
Aclarubicin
aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
G-CSF
G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
cytarabine
cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cladribine Injection
Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
Aclarubicin
aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
G-CSF
G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
cytarabine
cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. a diagnosis of AML according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML
2. Patients 60 years and older.
3. Patients NOT eligible for standard chemotherapy, defined as hematopoietic cell transplantation comorbidity index (HCT-CI) ≥ 3 or Patients NOT eligible for standard chemotherapy for other reasons (wish of patient).
4. White blood cell (WBC) ≤ 10 x109/L (prior hydroxyurea allowed for a maximum of 5 days, stop 2 days before start cladribine treatment)
5. Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:
* Serum creatinine ≤ 221.7 µmol/L (≤ 2.5 mg/dL ), unless considered AML-related -Serum bilirubin ≤ 2.5 x upper limit of normal (ULN), unless considered AML-
* related or due to Gilbert's syndrome
* Alanine transaminase (ALT) ≤ 2.5 x ULN, unless considered AML-related
6. WHO performance status 0, 1 or 2.
7. Patient is willing and able to use adequate contraception during and until 5 months after the last protocol treatment.
8. Written informed consent.
9. Patient is capable of giving informed consent.
Exclusion Criteria
2. Acute leukemia's of ambiguous lineage according to WHO 2016
3. Patient has symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement)
4. Blast crisis of chronic myeloid leukemia.
5. Diagnosis of any previous or concomitant malignancy is an exclusion criterion:
6. except when the patient completed successfully treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 6 months prior to randomization. OR
7. except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
8. Patients previously treated for AML (any antileukemic therapy including investigational agents), a short treatment period ( ≤ 5 days) with Hydroxyurea is allowed
9. Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea
10. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.)
11. Cardiac dysfunction as defined by:
* Myocardial infarction within the last 3 months of study entry, or
* Reduced left ventricular function with an ejection fraction \< 40% as measured by MUGA scan or echocardiogram or
* Unstable angina or
* New York Heart Association grade IV congestive heart failure or
* Unstable cardiac arrhythmias.
12. History of stroke or intracranial hemorrhage within 6 months prior to randomization.
13. Patient has a history of human immunodeficiency virus or active infection with Hepatitis C or B.
14. Patients known to be pregnant
15. Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance.
16. Patients with any serious concomitant medical condition which could, in the opinion of the investigator, compromise participation in the study.
17. Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
18. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
wanghua
Director, Head of hematology, Principal Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
wang hua, MD.
Role: PRINCIPAL_INVESTIGATOR
sun yat-sun university cancer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
hua wang, MD.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AML-2020
Identifier Type: -
Identifier Source: org_study_id